Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

CONCLUSIONS: The STIMULI trial did not meet its primary endpoint of improving PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in LD-SCLC. A short period on active treatment related to toxicity and treatment discontinuation likely affected the efficacy results.PMID:34562610 | DOI:10.1016/j.annonc.2021.09.011

Source: Ann Oncol - September 25, 2021 Category: Cancer & Oncology Authors: S Peters J-L Pujol U Dafni M D ómine S Popat M Reck J Andrade A Becker D Moro-Sibilot A Curioni-Fontecedro O Molinier K Nackaerts A Insa Moll á R Gervais G L ópez Vivanco J Madelaine J Mazieres M Faehling F Griesinger M Majem J L Gonz ález Larriba M P Source Type: research